(OTC: AVXT.OB) , (OTC BB:AENA), (OTC BB:ADXS) , (OTCBB: ALRG)

Turning Pennies into dollars: (OTC: AVXT.OB) , (OTC BB:AENA), (OTC BB:ADXS) , (OTCBB: ALRG)

Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559

For more info: http://avxt.realpennies.com

March 31, 2008--AVAX Technologies, Inc. (OTC Market: AVXT.OB) announces the appointment of Isabelle Fourthin, MD as Chief Medical Officer for Europe, Middle East and Africa (EMEA). Dr. Fourthin will be responsible for recruiting and overseeing European clinical sites for AVAX’s phase III registration study of MVax®, its autologous, hapten-modified melanoma vaccine, and for new indications for the AC-Vaccine technology as they develop.

AVAX Technologies, Inc. is a biotechnology company with operations in the United States and Europe. The Company is engaged in the research, clinical and commercial development of biological products and cancer therapeutics. AVAX’s AC Vaccine platform is a therapeutic cancer vaccine. In addition, the Company performs contract-manufacturing services for biological products for other pharmaceutical and biotechnology companies.

AVXT "closed yesterday at $0.09 per share."

For more info: http://aena.realpennies.com

March 31, 2008--Adrenalina (OTCBB: AENA.OB - News), a new innovative retail entertainment destination designed for extreme sports enthusiasts, announced today that it has signed six new lease agreements as part of the Company’s national expansion initiative.

Adrenalina pioneered and branded “The Extreme Store” concept, which showcases top-quality athletic apparel, equipment and accessories in a fun, engaging retail entertainment format. Building on the popularity of the Adrenalina TV program, the stores feature the first FlowRider® wave machines to be installed in retail locations. Adrenalina has the exclusivity for FlowRiders in retail locations. The stores average 10,000 square feet and carry the best in extreme sports apparel, footwear, equipment and accessories from industry leaders and fashion brands such as Quiksilver, Billabong, Volcom, O'Neil, Reef, Crocs and Ed Hardy.

AENA "closed yesterday at $1.35 per share."

For more info: http://adxs.realpennies.com

March 31, 2008--Advaxis Inc., (OTCBB: ADXS - News), a developmental biotechnology company, has been highlighted in the March 29th magazine edition of New Scientist.

The article, “Bugs Provoke the Immune System Into Fighting Cancer,” explains the Company’s technology, the advantages of using Listeria Monocytogenes as a platform, and the “Trojan Horse” effect that generates an attack on tumors after the patient’s immune system is infected by the bioengineered bacterium. The article discussed the first study conducted in man where both safety and preliminary efficacy data were generated.

“We are pleased New Scientist took such an interest in our approach,” commented Thomas Moore, chairman and CEO of Advaxis. “The full results of this trial will be presented at the American Association for Cancer Research next month. We plan to be moving Lovaxin C into larger, later stage trials later this year.”

Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes (“Lm”) cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board. Advaxis is developing therapeutic cancer vaccines that enhance the immune system’s cancer-fighting abilities through its proprietary Lm based system, which utilizes multiple simultaneous immunological mechanisms to fight cancer safely.

Advaxis’ lead Lm vaccine candidate – Lovaxin C – targets cervical and head and neck cancers. Current Lm vaccines in development target prostate, breast, ovarian and lung cancers. Advaxis has completed a Phase I/II clinical trial. The Lm platform will also have applications in the fields of infectious disease and autoimmune disorders.

ADXS "closed yesterday at $0.14 per share."

For more info: http://alrg.realpennies.com

March 31, 2008-- Allergy Research Group, Inc. (OTC BB:ALRG) today announced financial results for the year ending December 31, 2007.

ALRG announces revenues of $16,725,246 for the year ended December 31, 2007, an increase of 3% compared to $16,273,465 for the year ending December 31, 2006. The increase in sales is primarily due to the introduction of new products and promotional activities.

Cost of sales increased $146,836 to $10,340,573 for the year ended December 31, 2007, compared to $10,193,737 for the year ended December 31, 2006. The increase is due to increased sales. Gross profit margins were approximately 38% for 2007 and 37% for 2006. Gross profit margins increased slightly for the period over period comparison primarily as a result of increased prices on 50 items beginning in February 2007.

Net earnings after tax for December 31, 2007 and 2006 were $1,123,919 and $1,095,976, respectively. The increase is primarily due to the increased sales and gross profit offset by increased operating expenses and income tax expense.

Allergy Research Group, Inc. is an innovative leader in nutraceutical research and product formulation. Since its inception in 1979, the company has been noted for quality, hypoallergenic nutritional supplements and supplies products to physicians and healthcare practitioners worldwide.

ALRG "closed yesterday at $0.85 per share."

Read our full disclaimer at: http://www.realpennies.com/start.html

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html

Sponsored by: http://www.isthemarketopen.com

RealPennies .

Telephone: 1-800-940-6559

Matt /at/ realpennies.com